As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Citing people familiar with the matter, The Journal reported that Starboard approached former Pfizer CEO Ian Read and CFO ...
The drugmaker has cut costs already and has no coming product approvals or research that could offer a quick lift.
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
Activist investor Starboard Value has invested approximately $1 billion in Pfizer Inc (NYSE:PFE). This strategic move occurs ...
An activist invester has taken interest in pharma giant Pfizer, which despite becoming a household name during the pandemic ...
AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
Among the large drugmakers, Eli Lilly, AstraZeneca, Pfizer, Sanofi and Bayer are worth retaining in one’s portfolio.
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback